Eli Lilly and Company today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...
"The next day, my son convinced me to go to a walk-in clinic. They ran some tests and immediately sent me to the ER. I had ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...
"I told them I would be lying on the couch in the living room and to just come on in. They told me at the hospital that it ...
Ingestible electronics can sense and act inside the gut ...